The Science Behind SteadCalm™
SteadCalm™ pairs CBG (cannabigerol) with a water-soluble Vitamin E carrier. Vitamin E is an essential nutrient that supports healthy nerve structure and function. This page summarizes the published research on CBG as a compound and the role Vitamin E plays in nerve health.
The studies summarized below describe research on CBG as a compound, not on this product. CBG’s biological properties have been examined in laboratory and animal models. The role of Vitamin E in supporting nerve cell health is well established in the nutrition literature.
Educational content only. Not medical advice. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
How to Use This Page
Explore the published research on CBG as a compound, the role of Vitamin E in nerve health, and what topical formulation choices mean in practice. The research below is about CBG as a compound, not about this product.
CBG vs CBD
Both are non-intoxicating cannabinoids commonly used in topical products. They’re often discussed differently in research and formulation. This comparison is meant to help customers understand positioning, not to imply medical outcomes.
Why CBG is our focus
- Often positioned for “clarity + precision” in topical routines
- Fits a localized, nerve-first product philosophy
- Pairs well with application formats designed for control
Where CBD often shows up
- More widely used across topical wellness categories
- Commonly positioned for general calm and comfort
- May be included in broader blends and recovery products
Current research on cannabinoids and peripheral signaling pathways is still evolving. This page summarizes concepts discussed in scientific literature and is intended for educational purposes only. SteadCalm™ products are not intended to diagnose, treat, cure, or prevent any disease.
SteadCalm™ Micellar CBG Serum
One product. One focus. Built around the peer-reviewed CBG research above and made by pairing CBG with a water-soluble Vitamin E carrier for daily nerve wellness.
"I used to spend my days in bed. Now I can walk stairs, prepare meals, take care of my dogs."Danielle, Steadfast CBG user for 3 yearsIndividual experiences vary. Not a guarantee of results.
SteadCalm™ Micellar CBG Serum
2 FL OZ · 60 mL · Reserve below to lock in your launch option.
- ✓ 200mg CBG in a water-soluble, non-greasy formula
- ✓ A water-soluble CBG topical, not a generic CBD product
- ✓ Third-party tested · 30-day money-back guarantee
- ✓ Subscribe & save at $49/month · cancel any time
Free shipping over $100 · 30-day money-back guarantee
More CBG products in development
We are starting deliberately small. The SteadCalm™ Micellar CBG Serum is our proof of concept, built around the published CBG research summarized on this page. If it resonates with our community, the line expands.
More CBG formats may follow as the product line grows.
Want to be first to know when new formulations launch? Join the list, we send a few honest emails about the research and the product line, and nothing else.
Shop NowPeer-Reviewed CBG Research
Published, peer-reviewed research on CBG as a compound, from Yale School of Medicine and Penn State College of Medicine. Shared here as ingredient education. These studies were conducted in laboratory and animal models, not on SteadCalm.
Nav1.8, an analgesic target for nonpsychotomimetic phytocannabinoids
CBG demonstrated the most potent inhibition of Nav1.8 sodium channels in peripheral sensory neurons among all cannabinoids tested (CBD, CBG, CBN). Nav1.8 is a pain-signaling pathway. The FDA validated this target by approving Suzetrigine (JOURNAVX) in January 2025, the first oral Nav1.8 inhibitor for acute pain.
In this in-vitro study, CBG showed the most potent inhibition of Nav1.8 sodium channels among the cannabinoids tested. This is laboratory research on CBG as a compound, not a study of SteadCalm.
Mohammad-Reza Ghovanloo, PhD · Ghovanloo et al., PNAS, January 2025 · DOI: 10.1073/pnas.2416886122
Chronic Cannabigerol as an Effective Therapeutic for Cisplatin-Induced Neuropathic Pain
In this animal study, CBG administered for 7 and 14 consecutive days reduced neuropathic pain behaviors by 60 to 70% versus baseline (p < 0.001), with effects lasting 24+ hours after the last dose. The authors reported no tolerance and no significant weight change or adverse events in males or females.
“These findings support the study of CBG as a long-lasting neuropathic pain therapy which acts without tolerance in both males and females.”
Nachnani et al. · Pharmaceuticals, October 2023 · DOI: 10.3390/ph16101442
CBG Attenuates Mechanical Hypersensitivity from Chemotherapy-Induced Peripheral Neuropathy
In this animal study, CBG reduced neuropathic pain behaviors in both male and female subjects. The authors reported CBG was specifically anti-nociceptive for neuropathic pain rather than other pain types (persistent, thermal), via CB1, CB2, and alpha-2 adrenergic receptor engagement. A 1:1 CBG:CBD combination was more effective than CBG alone.
Sepulveda et al. · European Journal of Pain, October 2022 · DOI: 10.1002/ejp.2016
These statements reference published peer-reviewed research on CBG as a compound. They have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
Third-Party Lab Verified
Why SteadCalm CBG Serum?
Independent particle analysis (Malvern Panalytical, October 2025) measured the CBG particles in SteadCalm at approximately 7 nanometers. Published skin-science research describes particle-size thresholds for how topicals interact with skin: the smallest particles (roughly 4 to 20 nm) are described as able to permeate both intact and damaged skin, while larger particles generally require a carrier. SteadCalm's measured particle size falls within that smallest range, dispersed evenly through a water-soluble base that is non-greasy and absorbs quickly.
- Third-party tested
- Water-soluble
- Non-greasy
Particle-size distribution by number. Malvern Panalytical Zetasizer, October 8, 2025.
Malvern Panalytical· Tested October 8, 2025
Particle-size measurement of the formulation. The size thresholds shown reflect general published research on nanoparticles and skin, not testing of this product, and are not a measure of this product's clinical absorption, bioavailability, or therapeutic effect. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Research & References
A source-backed overview of how topical cannabinoids are discussed in published research, and how SteadCalm™ applies that thinking with a focus on daily nerve wellness.
Science Behind SteadCalm™ (PDF)
Download the full brief for citations, research themes (CB1/CB2, TRP channels such as TRPV1, peripheral signaling), and the rationale behind localized topical application.
Educational content only. Not medical advice. We do not claim to diagnose, treat, cure, or prevent any disease.
How to read this responsibly
- Many studies evaluate mechanisms and pathways, not identical commercial formulas.
- Topical response varies by application area, frequency, and individual sensitivity.
- If symptoms are severe, spreading, or persistent, consult a qualified clinician.